
Quoin Pharmaceuticals (NASDAQ:QNRX) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate clinical testing for its Investigational New Drug application for QRX003.
QRX003 is Quoin's investigational product for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no approved treatment or cure.